| Replimune Group, Inc.announced 8 Feb 2024 |
Initiate a Phase 3 confirmatory trial of RP1 in anti-PD1 failed melanoma skin cancers due after leader left |
Met31 Dec 2024 |
| Replimune Group, Inc.announced 8 Jan 2024 |
Submit BLA for RP1 in anti-PD1 failed melanoma due after leader left |
Met31 Dec 2024 |
| Replimune Group, Inc.announced 3 Aug 2023 |
Initiate clinical trials for RP3 in hepatocellular carcinoma |
Withdrawn30 Sep 2023 |
| Replimune Group, Inc.announced 3 Aug 2023 |
Disclose topline data from the registration-directed CERPASS clinical trial |
Met31 Dec 2023 |
| Replimune Group, Inc.announced 3 Aug 2023 |
Announce snapshot data for the IGNYTE clinical trial cohort |
Met31 Dec 2023 |
| Replimune Group, Inc.announced 3 Aug 2023 |
Provide a data update for the RP1 non-melanoma skin cancer cohort |
Met31 Dec 2023 |
| Replimune Group, Inc.announced 3 Aug 2023 |
Submit a Biologics License Application for RP1 |
Late31 Mar 2024 |
| Replimune Group, Inc.announced 3 Aug 2023 |
Supply RP1 to Incyte for the clinical trial |
Not met31 Mar 2024 |
| Replimune Group, Inc.announced 18 May 2023 |
Disclose additional Phase 2 development programs |
Not met31 Dec 2023 |
| Replimune Group, Inc.announced 18 May 2023 |
Submit a BLA for RP1 |
Not met31 Mar 2024 |
| Replimune Group, Inc.announced 9 Feb 2023 |
Announce data updates from ongoing RP1 skin cancer cohorts |
Late30 Sep 2023 |
| Replimune Group, Inc.announced 9 Feb 2023 |
Provide data update from RP2 Phase 1 clinical trial |
Met31 Dec 2023 |
| Replimune Group, Inc.announced 9 Feb 2023 |
Complete primary analysis of the IGNYTE clinical trial |
Late31 Mar 2024 |
| Replimune Group, Inc.announced 7 Dec 2022 |
Initiate three Phase 2 clinical trials for RP2/3 |
Not met30 Jun 2023 |
| Replimune Group, Inc.announced 3 Nov 2022 |
Present six-month follow-up data from the IGNYTE clinical trial cohort |
Met31 Dec 2022 |
| Replimune Group, Inc.announced 3 Nov 2022 |
Release data update for anti-PD1 failed non-melanoma skin cancers |
Late30 Jun 2023 |
| Replimune Group, Inc.announced 4 Aug 2022 |
Initiate Phase 2 development program with RP2/3 |
Not met31 Mar 2023 |
| Replimune Group, Inc.announced 4 Aug 2022 |
Initiate clinical trial for neoadjuvant treatment of CSCC |
Not met30 Jun 2023 |
| Replimune Group, Inc.announced 4 Aug 2022 |
Provide data update for the ARTACUS clinical trial |
Met30 Jun 2023 |
| Replimune Group, Inc.announced 19 May 2022 |
Release top line data for the CERPASS clinical trial |
Not met31 Mar 2023 |
| Replimune Group, Inc.announced 30 Mar 2022 |
Report initial data from the RP2 Phase 1 clinical trial cohort |
Met31 Dec 2022 |
| Replimune Group, Inc.announced 30 Mar 2022 |
Report initial data for the RP3 and Opdivo combination cohort |
Not met31 Dec 2022 |
| Replimune Group, Inc.announced 30 Mar 2022 |
Initiate the RP2/3 Phase 2 clinical program |
Not met31 Dec 2022 |
| Replimune Group, Inc.announced 30 Mar 2022 |
Report initial interim data from the registration-directed anti-PD1 failed cutaneous melanoma cohort |
Met31 Dec 2022 |
| Replimune Group, Inc.announced 30 Mar 2022 |
Report primary data from the CERPASS clinical trial in CSCC |
Late31 Mar 2023 |
| Replimune Group, Inc.announced 3 Feb 2022 |
Start enrolling patients for the RP3 and Opdivo combination trial |
Met31 Mar 2022 |
| Replimune Group, Inc.announced 3 Feb 2022 |
Release initial data from the IGNYTE NMSC cohort |
Met31 Mar 2022 |
| Replimune Group, Inc.announced 3 Feb 2022 |
Release initial directional data from the IGNYTE anti-PD-1 failed melanoma cohort |
Met31 Dec 2022 |
| Replimune Group, Inc.announced 3 Feb 2022 |
Release initial expansion patient data for the RP2 trial |
Met31 Dec 2022 |
| Replimune Group, Inc.announced 10 Jan 2022 |
Present initial data from RP2 expansion patients |
Met31 Dec 2022 |
| Replimune Group, Inc.announced 4 Nov 2021 |
Present detailed Phase 2 clinical development program |
Met31 Mar 2022 |
| Replimune Group, Inc.announced 4 Nov 2021 |
Provide updated and initial data from NMSC cohorts |
Met31 Mar 2022 |
| Replimune Group, Inc.announced 4 Nov 2021 |
Present initial data in anti-PD1 failed NMSC and NMSC transplant patients |
Met31 Mar 2022 |
| Replimune Group, Inc.announced 4 Nov 2021 |
Initiate broad clinical development program with RP2 and/or RP3 |
Not met30 Jun 2022 |
| Replimune Group, Inc.announced 4 Nov 2021 |
Release interim data for IGNYTE anti-PD1 failed melanoma cohort |
Met31 Dec 2022 |
| Replimune Group, Inc.announced 4 Nov 2021 |
Present data from expansion of Phase 1 studies with RP2 and RP3 |
Met31 Dec 2022 |
| Replimune Group, Inc.announced 4 Nov 2021 |
Trigger primary data analysis for CERPASS clinical trial |
Not met31 Dec 2022 |
| Replimune Group, Inc.announced 4 Nov 2021 |
Trigger primary analysis for IGNYTE anti-PD-1 failed melanoma cohort |
Late30 Jun 2023 |
| Replimune Group, Inc.announced 4 Feb 2021 |
Commence RP2 tech-transfer |
No record found31 Mar 2021 |
| Replimune Group, Inc.announced 4 Feb 2021 |
Present updated data for RP2 in combination with Opdivo |
Met30 Jun 2021 |
| Replimune Group, Inc.announced 4 Feb 2021 |
Present initial data for RP3 |
Late31 Dec 2021 |
| Replimune Group, Inc.announced 4 Feb 2021 |
Report initial data for RP1 in anti-PD1 failed NSCLC |
Being checked31 Dec 2021 |
| Replimune Group, Inc.announced 11 Jan 2021 |
Dose first patient in RP1 combination study in anti-PD1 failed NSCLC |
Not met31 Mar 2021 |
| Replimune Group, Inc.announced 11 Jan 2021 |
Dose first patient in RP1 monotherapy study in solid organ transplant recipients |
No record found31 Mar 2021 |
| Replimune Group, Inc.announced 11 Jan 2021 |
Announce initial development plan for RP2 and RP3 |
Not met30 Jun 2021 |
| Replimune Group, Inc.announced 11 Jan 2021 |
Present updated data from RP2 clinical trial |
Met30 Jun 2021 |
| Replimune Group, Inc.announced 11 Jan 2021 |
Decide whether to pursue MSI-H/dMMR tumors into registration-directed development |
Being checked31 Dec 2021 |
| Replimune Group, Inc.announced 11 Jan 2021 |
Present initial data from RP1 monotherapy study in solid organ transplant recipients |
Being checked31 Dec 2021 |
| Replimune Group, Inc.announced 11 Jan 2021 |
Present initial data from RP3 clinical trial |
Late31 Dec 2021 |
| Replimune Group, Inc.announced 11 Jan 2021 |
Provide primary data readout for RP1 in combination with Libtayo in CSCC |
Being checked31 Dec 2022 |